JNJ vs PFE: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
Johnson & Johnson · Healthcare
$270.68
+5.7% upside to fair value
Med Conviction
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
PFE |
| Current Price |
$270.68 |
$27.64 |
| Fair Value Estimate |
$286.05 |
$30.94 |
| Upside to Fair Value |
+5.7%
|
+12.0%
|
| Market Cap |
$652.3B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
20.2x
|
17.4x
|
| Price / Sales |
6.7x
|
2.5x
|
| Price / FCF |
35.3x
|
14.3x
|
| Revenue Growth YoY |
+6.6%
|
+2.6%
|
| Gross Margin |
67.9%
|
71.3%
|
| Operating Margin |
26.8%
|
25.1%
|
| Return on Equity |
25.7%
|
4.9%
|
| Dividend Yield |
1.95% |
6.22% |
| FCF Yield |
2.83%
|
6.97%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Johnson & Johnson is a 141,700-employee healthcare holding company operating two segments, Innovative Medicine (immunology, oncology, neuroscience, infectious disease, cardiovascular and metabolism, pulmonary hypertension) and MedTech (interventional solutions, orthopaedics, surgery, vision), founded in 1887 and headquartered in New Brunswick, New Jersey. Business quality is high on fundamentals:…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
JNJ |
PFE |
| Zone Low |
$214.54 |
$23.21 |
| Zone High |
$243.14 |
$26.30 |
| In Buy Zone? |
No
|
No
|